Global Biosimilars Market (2022-2027) by Product, Indication, Manufacturing, and Geography, IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis

Global Biosimilars Market (2022-2027) by Product, Indication, Manufacturing, and Geography, IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis


The Global Biosimilars Market is estimated to be USD 3.34 Bn in 2022 and is expected to reach USD 10.17 Bn by 2027, growing at a CAGR of 24.94%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the Global Biosimilars Market stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.
As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

The Global Biosimilars Market is segmented based on Product, Indication, Manufacturing, and Geography.

  • By Product, the market is classified into Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides.
  • By Indication, the market is classified into Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.
  • By Manufacturing, the market is classified into Contract Manufacturing and In-House Manufacturing.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific.
Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are AMEGA Biotech, Amgen Inc., Innovent Biologics, Inc., GE Healthcare, Merck & Co., Inc., Mylan N.V., etc.

Countries Studied
  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)
IGR Competitive Quadrant

The report includes IGR Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Biosimilars Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
Infogence Global Research analyses the Global Biosimilars Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
Based on the SWOT analysis conducted on the industry and industry players, Infogence Global Research has devised suitable strategies for market growth.

Why buy this report?
  • The report offers a comprehensive evaluation of the Global Biosimilars Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using IGR Positioning Quadrants, Infogence's Proprietary competitive positioning tool.
Report Highlights:
  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 IGR Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Growing Pressure to Reduce Healthcare Expenditure
4.1.2 Growing Demands for Pharmaceutical Drugs
4.1.3 Supportive Government Initiative and Awareness Creating Programs in the Developing Economies
4.2 Restraints
4.2.1 Stringent Regulatory Requirements Adversely Affecting Investment in the Biosimilars Market
4.2.2 Resistance from Biologics Manufacturers
4.3 Opportunities
4.3.1 Lower Cost Biosimilars Drugs than Original Biologics
4.3.2 Emergence of Bio-betters Drugs
4.4 Challenges
4.4.1 Complexities in Manufacturing
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Biosimilars Market, By Product
6.1 Introduction
6.2 Recombinant Glycosylated Proteins
6.2.1 Erythropoietin
6.2.2 Follitropin
6.2.3 Monoclonal Antibodies
6.3 Recombinant Non-Glycosylated Proteins
6.3.1 Granulocyte Colony-Stimulating Factor
6.3.2 Insulin
6.3.3 Interferons
6.3.4 Recombinant Human Growth Hormone
6.4 Recombinant Peptides
6.4.1 Calcitonin
6.4.2 Glucagon
7 Global Biosimilars Market, By Indication
7.1 Introduction
7.2 Autoimmune Diseases
7.3 Blood Disorders
7.4 Chronic Diseases
7.5 Growth Hormone Deficiency
7.6 Infectious Diseases
7.7 Oncology
8 Global Biosimilars Market, By Manufacturing
8.1 Introduction
8.2 Contract Manufacturing
8.3 In-House Manufacturing
9 Americas’ Biosimilars Market
9.1 Introduction
9.2 Argentina
9.3 Brazil
9.4 Canada
9.5 Chile
9.6 Colombia
9.7 Mexico
9.8 Peru
9.9 United States
9.10 Rest of Americas
10 Europe’s Biosimilars Market
10.1 Introduction
10.2 Austria
10.3 Belgium
10.4 Denmark
10.5 Finland
10.6 France
10.7 Germany
10.8 Italy
10.9 Netherlands
10.10 Norway
10.11 Poland
10.12 Russia
10.13 Spain
10.14 Sweden
10.15 Switzerland
10.16 United Kingdom
10.17 Rest of Europe
11 Middle East and Africa’s Biosimilars Market
11.1 Introduction
11.2 Egypt
11.3 Israel
11.4 Qatar
11.5 Saudi Arabia
11.6 South Africa
11.7 United Arab Emirates
11.8 Rest of MEA
12 APAC’s Biosimilars Market
12.1 Introduction
12.2 Australia
12.3 Bangladesh
12.4 China
12.5 India
12.6 Indonesia
12.7 Japan
12.8 Malaysia
12.9 Philippines
12.10 Singapore
12.11 South Korea
12.12 Sri Lanka
12.13 Thailand
12.14 Taiwan
12.15 Rest of Asia-Pacific
13 Competitive Landscape
13.1 IGR Competitive Quadrant
13.2 Market Share Analysis
13.3 Strategic Initiatives
13.3.1 M&A and Investments
13.3.2 Partnerships and Collaborations
13.3.3 Product Developments and Improvements
14 Company Profiles
14.1 AMEGA Biotech
14.2 Amgen Inc.
14.4 Biocon Ltd.
14.5 Boehringer Ingelheim International GmbH
14.6 Celltrion Healthcare Co., Ltd.
14.7 Coherus BioSciences, Inc.
14.8 Eli Lilly and Co.
14.9 Fresenius SE & Co. KGaA
14.10 Fujifilm Kyowa Kirin Biologics Co. Ltd.
14.11 GE Healthcare
14.12 Innovent Biologics, Inc.
14.13 Intas Pharmaceuticals Ltd.
14.14 Merck & Co., Inc.
14.15 Mylan N.V.
14.16 Novartis Ag
14.17 Pfizer Inc.
14.18 Samsung Bioepis Co., Ltd.
14.19 Sandoz International GmbH
14.20 Stada Arzneimittel Ag
14.21 Teva Pharmaceutical Industries Ltd.
14.22 Viatris, Inc.
15 Appendix
15.1 Questionnaire

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings